Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
What would you recommend as a subsequent therapy for patients with ROS-1 gene re-arrangement after progression on crizotinib?
Answer from: Medical Oncologist at Community Practice
Clinical trial (entrectinib, repotrectinib) or lorlatinib
Sign in or Register to read more
5520
Related Questions
What systemic therapy would you offer to a patient with metastatic EGFR exon 19 deleted NSCLC to the brain with isolated CNS progression while on osimertinib 80 mg and progressed through WBRT?
In a patient with node-positive limited-stage small cell lung cancer, how do you approach radiation in a patient whose small primary tumor resolves after one cycle of chemotherapy?
For NSCLC patients treated with neoadjuvant chemoimmunotherapy and surgery with ypN2 disease, what factors would cause you to recommend PORT?
How are you incorporating Tumor Treating Fields for locally progressive/metastatic NSCLC, if at all?
In stage IV oligometastatic NSCLC, when considering local consolidative therapies to the primary tumor, do providers typically stage the mediastinum at diagnosis or after initial systemic therapy (assuming no progression)?
What would be the recommended sequencing of adjuvant chemotherapy, osimertinib, and postoperative radiation for a patient with NSCLC who was upstaged to stage III following resection with negative margins?
Would you consider "consolidation" chemoradiotherapy for a Stage III NSCLC that was initially felt to be too extensive for definitive intent radiotherapy who later experiences a radiographic complete response to carboplatin, paclitaxel, and pembrolizumab?
How well does a negative non-contrast MRI of the brain exclude metastasis in a patient with squamous cell carcinoma of the lung?
Given the results of LU002 presented at ASCO 2024, are there situations and/or patient subgroups who still derive benefit from local consolidative therapy for oligometastatic NSCLC?
What is your approach to radiographically suspicious lung nodules for which initial biopsy was negative for malignancy?